Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trialResearch in context

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trialResearch in context

Summary: Background: The SARS-CoV-2 virus continues to evolve with recent variants such as the omicron sub-variants potentially exhibiting increased transmissibility. Of note, the XBB.1.5 variant has been associated with vaccine-breakthrough cases. We utilised the same platform previously used to d...

Full description

Saved in:
Bibliographic Details
Main Authors: Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Rammohan Reddy Mogulla, Vijay Yerroju, Chirag Dhar, Siddalingaiah Ningaiah, Mallikarjuna Panchakshari, Chandrashekhar S. Gillurkar, Manish Narang, Shivnitwar Sachin Kisan, A. Venkateshwar Rao
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:The Lancet Regional Health - Southeast Asia
Subjects:
Randomised controlled trial
COVID-19
XBB.1.5 variant
Subunit vaccine
Booster
Online Access:http://www.sciencedirect.com/science/article/pii/S2772368225001131
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772368225001131

Similar Items